Sector
PharmaceuticalsOpen
₹65.5Prev. Close
₹64.81Turnover(Lac.)
₹16.89Day's High
₹69.5Day's Low
₹64.1352 Week's High
₹8152 Week's Low
₹52Book Value
₹14.83Face Value
₹10Mkt Cap (₹ Cr.)
402.8P/E
47.65EPS
1.36Divi. Yield
01 Sep 2023
12:00 AM
AGM
Announcement Date: 01 Sep, 2023
24 Apr 2024
12:00 AM
Board Meeting
Agenda : Audited Result
5 Sep 2023
12:00 AM
BookCloser
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 61.03 | 61.03 | 61.03 | 61.03 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 21.24 | 9.61 | -12.62 | -11.4 |
Net Worth | 82.27 | 70.64 | 48.41 | 49.63 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 22.44 | 25.93 | 11.14 | 2.25 |
yoy growth (%) | -13.46 | 132.75 | 394.37 | 9.43 |
Raw materials | -0.03 | -0.5 | -0.79 | -1.66 |
As % of sales | 0.14 | 1.94 | 7.16 | 74.03 |
Employee costs | -6.49 | -5.76 | -5.06 | -3.02 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -1.21 | 4.4 | -11.85 | -21.69 |
Depreciation | -6.45 | -4.84 | -3.9 | -3.87 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | 0.71 | -0.28 | 52.29 | -18.35 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -13.46 | 132.75 | 394.37 | 9.43 |
Op profit growth | -28.29 | -213.09 | -24.38 | 35.6 |
EBIT growth | -93.72 | -156.37 | -33.78 | 22.48 |
Net profit growth | -111.27 | -190.94 | -40.35 | 3.82 |
| Particulars (Rupees in Crores.) | Mar-2010 | Mar-2009 | Mar-2008 | Mar-2007 | Mar-2006 |
|---|---|---|---|---|---|
Gross Sales | 6.57 | 6.01 | 8.22 | 13.46 | 13.19 |
Excise Duty | 0 | 0 | 0 | 0.62 | 0.82 |
Net Sales | 6.57 | 6.01 | 8.22 | 12.82 | 12.36 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 2.1 | 4.63 | 2.17 | 9.31 | 0.09 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.45 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,520.1 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.15 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.6 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,639.05 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Independent Director
Kavita Shah
Non Executive Director
Jignesh Anantray Goradia
Chairman (Non-Executive)
Azadar Hussain Khan
Independent Director
Chintan Jitendra Shah
Company Sec. & Compli. Officer
Abdul Gafoor Mohammad
Independent Director
JAGRUTI PRASHANT SHETH
Non Executive Director
Rakeshchandra Jagdishprasad Sinha
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Zenotech Laboratories Ltd
Summary
Zenotech Laboratories Limited (Formerly Sunline Technologies Limited) was established in June, 1989. The Company is a pharmaceutical specialty generic injectables company engaged in the area of manufacturing biotechnology products. The Companys injectables product portfolio primarily serves niche therapy areas like oncology and anesthesiology.During financial year 2004-05, the Honble High Court of Andhra Pradesh sanctioned the Scheme of Amalgamation with M/s. Zenotech Technologies Limited with effect from November 1st , 2003. The Company had issued 91,82,500 equity shares to erstwhile shareholders of M/s. Zenotech Laboratories Pvt. Ltd. and resultant, the name of Company was changed to Zenotech Laboratories Ltd. with effect from August 10, 2004.M/s, Credence Pharmaceuticals Limited and M/s, Hemarus Healthcare Private Limited were merged with the Company, on May 2, 2006 through Scheme of Amalgamation, effective from October 1, 2005. 15 generic chemical oncology products were launched by the Company in India. Besides, the Company launched its anesthesia range of products during 2006.Consequent to the consummation of the merger of Ranbaxy Laboratories Limited into SPIL on March 24, 2015, SPIL indirectly acquired 46.84 percent of the voting rights held by Ranbaxy in, and control over the Company and became Promoter of the Company along with Daiichi Sankyo Company Limited and resultant, the Open Offer concluded in August 2015.The Company started production from its newly commissio
Read More
What is the Zenotech Laboratories Ltd share price today?
The Zenotech Laboratories Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹66 today.
What is the Market Cap of Zenotech Laboratories Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Zenotech Laboratories Ltd is ₹402.80 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Zenotech Laboratories Ltd?
The PE and PB ratios of Zenotech Laboratories Ltd is 47.65 and 4.37 as of 22 Jul ‘24
What is the 52 Week High and Low of Zenotech Laboratories Ltd?
The 52-week high/low is the highest and lowest price at which a Zenotech Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Zenotech Laboratories Ltd is ₹52 and ₹81 as of 22 Jul ‘24
What is the CAGR of Zenotech Laboratories Ltd?
Zenotech Laboratories Ltd's CAGR for 5 Years at 32.78%, 3 Years at 10.22%, 1 Year at 13.34%, 6 Month at -13.83%, 3 Month at 1.01% and 1 Month at 6.33%.
What is the shareholding pattern of Zenotech Laboratories Ltd?
The shareholding pattern of Zenotech Laboratories Ltd is as follows:
Promoters - 68.84 %
Institutions - 0.99 %
Public - 30.17 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
